跳轉至內容
Merck

Advances in amblyopia: what have we learned from PEDIG trials?

Pediatrics (2013-02-06)
Kammi B Gunton
摘要

Amblyopia is the most common cause of preventable visual loss in children. This article reviews treatment options, durations, and efficacy in randomized multicentered trials conducted by the Pediatric Eye Disease and Investigator Group in the last decade. Parents and patients should be counseled that many forms of treatment are efficacious, allowing the option of choice of best-tolerated treatment method. Compliance is key to successful treatment. The course of treatment is likely at least 6-12 months, with yearly follow-up suggested once amblyopia has been treated to monitor for regression.

材料
產品編號
品牌
產品描述

Supelco
阿托品标准液 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
峰鉴别用阿托品, European Pharmacopoeia (EP) Reference Standard